With the rapid development of technology and the changes in people's lifestyles, more and more eye diseases are caused by overuse of the eyes, so that the market demand for ophthalmic drugs continues to grow, and market competition is becoming more intense. While paying attention to the effect of drug treatment, pharmaceutical companies can seek market breakthroughs in eye drop bottles.
At present, most of the market share of ophthalmic drugs is controlled by international giants such as Novartis, Santian, Bayer and Allergan. Although the ophthalmic drug market accounts for a small proportion of the retail market, with the intensification of aging and long-term overuse of eyes, the ophthalmic drug market will show a trend of "small areas and big development". In June 2021, Hengrui Pharmaceuticals, one of China’s largest pharmaceutical companies, announced that its subsidiary Chengdu Shengdi Pharmaceutical Co., Ltd. received the “Notice of Drug Clinical Trial Approval” approved and issued by the National Medical Products Administration, and approved the development of an HR19034 eye drop. A phase III clinical trial for the prevention and control of the progression of myopia in children. The active ingredients of the product mainly interact with the receptors of the sclera, choroid and retina to inhibit the growth of the eye axis, thereby delaying the progression of myopia. At present, no similar products at home and abroad have been approved for listing. This drug will surely stir up the ophthalmic drug market after it goes on the market, triggering more intense market competition.
The competition in the ophthalmic drug market tests not only the brand strength and influence, but also the patient's medication experience. Commonly used ophthalmic drugs are basically the same in efficacy, but eye drops are high-risk medications. The softness of the eye drop bottle and the amount of dripping from the bottle will affect the patient's drug delivery experience.
On the whole, pharmaceutical companies want to gain a share in the ophthalmic drug market. In addition to strictly controlling the quality of drugs, the choice of eye drop bottles is also crucial. Good packaging will play a role in improving the competitiveness of the product market. Important role.
没有评论:
发表评论